A detailed history of Barclays PLC transactions in Allakos Inc. stock. As of the latest transaction made, Barclays PLC holds 1,159,354 shares of ALLK stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,159,354
Previous 91,297 1169.87%
Holding current value
$1.45 Million
Previous $249,000 486.35%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $1.09 Million - $3.45 Million
1,068,057 Added 1169.87%
1,159,354 $1.46 Million
Q4 2023

Feb 15, 2024

SELL
$1.72 - $3.18 $546,390 - $1.01 Million
-317,669 Reduced 77.68%
91,297 $249,000
Q3 2023

Nov 07, 2023

SELL
$2.13 - $5.55 $205,076 - $534,354
-96,280 Reduced 19.06%
408,966 $928,000
Q2 2023

Aug 03, 2023

BUY
$3.6 - $5.25 $161,704 - $235,819
44,918 Added 9.76%
505,246 $2.2 Million
Q1 2023

May 04, 2023

BUY
$4.3 - $8.27 $242,958 - $467,271
56,502 Added 13.99%
460,328 $2.05 Million
Q4 2022

Feb 13, 2023

BUY
$5.97 - $8.42 $2.27 Million - $3.19 Million
379,451 Added 1556.72%
403,826 $3.4 Million
Q3 2022

Nov 03, 2022

BUY
$3.02 - $5.84 $41,624 - $80,492
13,783 Added 130.13%
24,375 $150,000
Q2 2022

Aug 12, 2022

SELL
$2.6 - $6.14 $62,111 - $146,678
-23,889 Reduced 69.28%
10,592 $33,000
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $89,245 - $172,342
-17,568 Reduced 33.75%
34,481 $196,000
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $271,300 - $3.55 Million
31,731 Added 156.17%
52,049 $509,000
Q3 2021

Nov 09, 2021

BUY
$76.53 - $110.43 $491,399 - $709,071
6,421 Added 46.2%
20,318 $2.15 Million
Q2 2021

Aug 13, 2021

SELL
$85.37 - $114.1 $3.49 Million - $4.66 Million
-40,883 Reduced 74.63%
13,897 $1.19 Million
Q1 2021

May 13, 2021

BUY
$109.73 - $153.66 $614,378 - $860,342
5,599 Added 11.38%
54,780 $6.29 Million
Q4 2020

Feb 11, 2021

SELL
$79.58 - $152.45 $205,316 - $393,320
-2,580 Reduced 4.98%
49,181 $6.89 Million
Q3 2020

Nov 12, 2020

BUY
$66.43 - $90.99 $2.53 Million - $3.46 Million
38,014 Added 276.53%
51,761 $4.22 Million
Q2 2020

Aug 12, 2020

SELL
$44.04 - $80.69 $939,549 - $1.72 Million
-21,334 Reduced 60.81%
13,747 $987,000
Q1 2020

May 13, 2020

BUY
$44.49 - $93.39 $667,394 - $1.4 Million
15,001 Added 74.71%
35,081 $1.56 Million
Q4 2019

Feb 10, 2020

BUY
$66.49 - $137.73 $542,225 - $1.12 Million
8,155 Added 68.39%
20,080 $1.92 Million
Q3 2019

Nov 14, 2019

SELL
$31.0 - $89.73 $16,678 - $48,274
-538 Reduced 4.32%
11,925 $938,000
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $200,232 - $248,788
5,562 Added 80.6%
12,463 $541,000
Q1 2019

May 15, 2019

SELL
$33.79 - $51.99 $715,841 - $1.1 Million
-21,185 Reduced 75.43%
6,901 $280,000
Q4 2018

Feb 14, 2019

BUY
$31.59 - $62.65 $12,193 - $24,182
386 Added 1.39%
28,086 $1.47 Million
Q3 2018

Nov 14, 2018

BUY
$31.25 - $47.64 $865,625 - $1.32 Million
27,700 New
27,700 $1.25 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $106M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.